New drug with chemotherapy and immunotherapy for lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new drug combined with standard chemotherapy and immune therapy for people with diffuse large B-cell lymphoma. The goal is to see if the combination is safe and helps shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have been diagnosed with diffuse large B-cell lymphoma.
- You have at least one tumor that can be measured on scans.
- You have recovered from side effects of prior cancer treatments.
- Your heart, kidney, and liver function are adequate (no severe heart problems, normal heart pumping ability, and urine protein is low).
- You can provide a sample of your tumor tissue from a past biopsy (within 3 years) or agree to a new biopsy.
- If you were treated with chemotherapy, immunotherapy, or other cancer drugs, your last treatment was at least 4 weeks ago.
- You are not pregnant, not breastfeeding, and agree to use birth control during and for 6 months after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This trial compares a new targeted medicine (JS203) combined with chemotherapy against a standard treatment (rituximab) with chemotherapy for people whose large B-cell lymphoma has returned or not responded. The goal is to see if the new combination works better and to offer a possible new option.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
This trial studies a specific treatment plan to see how well it works for adults with newly diagnosed non-Hodgkin lymphoma that has a high amount of disease. It may help by aiming to control lymphoma more effectively, especially when it is widespread.
This trial tests a new combination of drugs (R-CMOP) for people who have just been diagnosed with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) and have not yet received any treatment for it. The goal is to see if this treatment works well and is safe.
This trial is testing a new drug called TQB2825 given alongside standard chemotherapy (R-CHOP or GemOx) for people with diffuse large B-cell lymphoma (DLBCL) or a related type called grade 3b follicular lymphoma. The goal is to see if adding this new drug is safe and works better than standard treatment alone.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.